Recovery in Stroke Patients Treated With Fluoxetine Versus Placebo

Elsnhory, Ahmed Bostamy; Hasan, Maruf; Hagrass, Abdulrahman Ibrahim; Hanbal, Ahmed; Fathy, Anas; Ahmed, Eslam Mohammed Yousef; Ouerdane, Yassamine; Ragab, Khaled Mohamed; Elfil, Mohamed; Doheim, Mohamed Fahmy

doi:10.1097/nrl.0000000000000451

Cited by 1 publication

(1 citation statement)

References 56 publications

(135 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on these descriptive data, we identified the largest systematic reviews within each medical disease. Data on primary and secondary outcome measures for these 73 systematic reviews are presented in eTable 7 in Supplement 2 for treatment of depression and in eTable 8 in Supplement 2 for prevention of depression.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and Safety of Antidepressants in Patients With Comorbid Depression and Medical Diseases

Köhler-Forsberg,

Stiglbauer,

Brasanac

et al. 2023

JAMA Psychiatry

View full text Add to dashboard Cite

ImportanceEvery third to sixth patient with medical diseases receives antidepressants, but regulatory trials typically exclude comorbid medical diseases. Meta-analyses of antidepressants have shown small to medium effect sizes, but generalizability to clinical settings is unclear, where medical comorbidity is highly prevalent.ObjectiveTo perform an umbrella systematic review of the meta-analytic evidence and meta-analysis of the efficacy and safety of antidepressant use in populations with medical diseases and comorbid depression.Data SourcesPubMed and EMBASE were searched from inception until March 31, 2023, for systematic reviews with or without meta-analyses of randomized clinical trials (RCTs) examining the efficacy and safety of antidepressants for treatment or prevention of comorbid depression in any medical disease.Study SelectionMeta-analyses of placebo- or active-controlled RCTs studying antidepressants for depression in individuals with medical diseases.Data Extraction and SynthesisData extraction and quality assessment using A Measurement Tool for the Assessment of Multiple Systematic Reviews (AMSTAR-2 and AMSTAR-Content) were performed by pairs of independent reviewers following PRISMA guidelines. When several meta-analyses studied the same medical disease, the largest meta-analysis was included. Random-effects meta-analyses pooled data on the primary outcome (efficacy), key secondary outcomes (acceptability and tolerability), and additional secondary outcomes (response and remission).Main Outcomes and MeasuresAntidepressant efficacy presented as standardized mean differences (SMDs) and tolerability (discontinuation for adverse effects) and acceptability (all-cause discontinuation) presented as risk ratios (RRs).ResultsOf 6587 references, 176 systematic reviews were identified in 43 medical diseases. Altogether, 52 meta-analyses in 27 medical diseases were included in the evidence synthesis (mean [SD] AMSTAR-2 quality score, 9.3 [3.1], with a maximum possible of 16; mean [SD] AMSTAR-Content score, 2.4 [1.9], with a maximum possible of 9). Across medical diseases (23 meta-analyses), antidepressants improved depression vs placebo (SMD, 0.42 [95% CI, 0.30-0.54]; I2 = 76.5%), with the largest SMDs for myocardial infarction (SMD, 1.38 [95% CI, 0.82-1.93]), functional chest pain (SMD, 0.87 [95% CI, 0.08-1.67]), and coronary artery disease (SMD, 0.83 [95% CI, 0.32-1.33]) and the smallest for low back pain (SMD, 0.06 [95% CI, 0.17-0.39]) and traumatic brain injury (SMD, 0.08 [95% CI, −0.28 to 0.45]). Antidepressants showed worse acceptability (24 meta-analyses; RR, 1.17 [95% CI, 1.02-1.32]) and tolerability (18 meta-analyses; RR, 1.39 [95% CI, 1.13-1.64]) compared with placebo. Antidepressants led to higher rates of response (8 meta-analyses; RR, 1.54 [95% CI, 1.14-1.94]) and remission (6 meta-analyses; RR, 1.43 [95% CI, 1.25-1.61]) than placebo. Antidepressants more likely prevented depression than placebo (7 meta-analyses; RR, 0.43 [95% CI, 0.33-0.53]).Conclusions and RelevanceThe results of this umbrella systematic review of meta-analyses found that antidepressants are effective and safe in treating and preventing depression in patients with comorbid medical disease. However, few large, high-quality RCTs exist in most medical diseases.

show abstract

Section: Resultsmentioning

confidence: 99%